AB 1470: Cannabis testing.
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2020-09-04
|
Date
|
Status
|
|---|---|
| Sep 29, 2020 | Vetoed by Governor. |
| Sep 14, 2020 | Enrolled and presented to the Governor at 4 p.m. |
| Aug 31, 2020 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 76. Noes 0. Page 5423.). |
| Aug 30, 2020 | In Assembly. Concurrence in Senate amendments pending. |
| Aug 30, 2020 | Read third time. Passed. Ordered to the Assembly. (Ayes 39. Noes 0.). |
| Aug 27, 2020 | Read second time. Ordered to third reading. |
| Aug 26, 2020 | Read third time and amended. Ordered to second reading. |
| Aug 25, 2020 | Read second time. Ordered to third reading. |
| Aug 24, 2020 | Read third time and amended. Ordered to second reading. |
| Aug 11, 2020 | Read second time. Ordered to third reading. |
| Aug 10, 2020 | From committee: Do pass. (Ayes 9. Noes 0.) (August 8). |
| Jun 23, 2020 | Referred to Com. on B., P. & E.D. |
| Jan 23, 2020 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Jan 23, 2020 | Read third time. Passed. Ordered to the Senate. (Ayes 76. Noes 0. Page 3865.) |
| Jan 15, 2020 | Read second time. Ordered to third reading. |
| Jan 14, 2020 | From committee: Do pass. (Ayes 18. Noes 0.) (January 14). |
| Apr 23, 2019 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| Apr 22, 2019 | Re-referred to Com. on B. & P. |
| Apr 12, 2019 | From committee chair, with author's amendments: Amend, and re-refer to Com. on B. & P. Read second time and amended. |
| Apr 1, 2019 | Re-referred to Com. on B. & P. |
| Mar 28, 2019 | Referred to Com. on B. & P. |
| Feb 25, 2019 | Read first time. |
| Feb 23, 2019 | From printer. May be heard in committee March 25. |
| Feb 22, 2019 | Introduced. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 31, 2020 | AB 1470 Quirk Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 30, 2020 | Assembly 3rd Reading AB1470 Quirk By Leyva | Senate Floor |
Passed |
|
| Aug 8, 2020 | Do pass | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
|
| Jan 23, 2020 | AB 1470 Quirk Assembly Third Reading | Assembly Floor |
Passed |
|
| Jan 14, 2020 | Do pass. | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
GOVERNOR'S VETO
GV Bill Id:AB 1470
Author:(Quirk)
As Enrolled Ver:September 4, 2020
2/3 vote
SUMMARY:
- Specifies that "final form" means unpackaged cannabis product as it will be consumed.
The Senate Amendments:
- Adds double-jointing language with AB 1458 (Quirk) of the current legislative session.
- Addresses implementation issues by removing vaporized devices from the definition of final form in order to ensure accurate testing for potential lead, mercury, or harmful material contamination.
Governor's Veto Message:
AB 1470 would provide that cannabis goods do not have to be in final retail packaging when being tested by laboratories to ensure compliance with current health and safety standards.
This bill conflicts with current regulations promulgated by cannabis licensing authorities that prevent contaminated and unsafe products from entering the retail market. While I support reducing packaging waste, allowing products to be tested not in their final retail form could result in consumer harm and have a disproportionate impact on small operators.
I have directed my Administration to consolidate the state regulatory entities that currently enforce cannabis health and safety standards to pursue all appropriate measures to ease costs and reduce unnecessary packaging. This proposal should be considered as part of that process.
COMMENTS:
State Regulation of Cannabis. In 1996, California first legalized cannabis for medical consumption via Proposition 215, also known as the Compassionate Use Act (the Act). Proposition 215 protected qualified patients and primary caregivers from prosecution related to the possession and cultivation of cannabis for medicinal purposes. In 2003, the Legislature authorized the formation of medical marijuana cooperatives—nonprofit organizations that cultivate and distribute marijuana for medical uses to their members through dispensaries.
In 2015, the Legislature passed the Medical Cannabis Regulation and Safety Act (MCRSA). For the first time, MCRSA established a comprehensive, statewide licensing and regulatory framework for the cultivation, manufacture, transportation, testing, distribution, and sale of medicinal cannabis to be administered by the Bureau within the Department of Consumer Affairs, Department of Public Health, and California Department of Food and Agriculture.
Shortly following the passage of MCRSA in November 2016, California voters passed Proposition 64, the "Control, Regulate and Tax Adult Use of Marijuana Act" (Proposition 64), which legalized adult-use cannabis. Less than a year later in June 2017, the California State Legislature passed a budget trailer bill, SB 94 (Committee on Budget and Fiscal Review, Chapter 27, Statutes of 2017), that integrated MCRSA with Prop 64 to create MAUCRSA, the current regulatory structure for both medicinal and adult-use cannabis. Beginning in 2018, Proposition 64 permitted adults 21 years of age or older can legally grow, possess, and use cannabis for nonmedical purposes, with certain restrictions.
Final Form and Testing. MAUCRSA requires cannabis in its final form to be laboratory tested prior to sale. Currently, the California Bureau of Cannabis Control has promulgated regulations that determine final form by how a consumer purchases the product from a retail location. Practically, this means that manufactured cannabis products are delivered to labs for testing in sealed, labeled retail packaging. The regulations also define a "packaged unit" as the final form of the product as it would be sold to the consumer. This includes identical packaging branding of the manufactured cannabis goods in their final form. (California Code of Regulations, Title 16, Section 5708)
This bill provides clarity to the above regulations by statutorily defining final form as the unpackaged product as it will be consumed. Further, this bill states that the cannabis or cannabis product does not have to be to the laboratory in the final retail packaging or, if applicable, within its vaporizer device, to be considered in its final form. This will prevent cannabis manufacturers from unnecessarily spending resources and creating waste to full package a product when the laboratory must extract the product from its packaging for testing. Finally, this bill will allow for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
According to the Author:
This bill is sponsored by the California Cannabis Manufacturer's Association. According to the author, "The regulated cannabis industry is at risk. The legal market has been unable to drive out the remnants of underground cannabis markets, and there are serious concerns that under the regulations as currently structured, the black market may never be driven out. AB 1470 makes commonsense changes to the laws regulating cannabis testing so that cannabis can be tested in a batch. Currently manufactured cannabis product, like extract sold in vaporizer cartridges, must be sent to laboratories in their final retail packaged form. This means labs are forced to break open cartridges, or make other laborious efforts to get at the cannabis product being tested. AB 1470 spares manufactures and laboratories the expense, making the regulated market stronger and making good on the direction the voters approved under Proposition 64."
Arguments in Support:
According to Southern California Coalition, "[a]llows cannabis manufacturers to manage testing in a more accessible and less expensive manner than is currently available to them. It is a badly needed adjustment of business practices. By allowing final form testing without packaging, you are following the practice of many other industries. [This bill] does not waive testing or quality assurance protocols. It merely simplifies the process and will save the industry time and money.
Arguments in Opposition:
None on file.
FISCAL COMMENTS:
None. This bill was keyed non fiscal by Legislative Counsel.
VOTES:
ASM BUSINESS AND PROFESSIONS: 18-0-1
YES: Low, Brough, Arambula, Bloom, Chen, Chiu, Cunningham, Eggman, Fong, Gipson, Gloria, Grayson, Holden, Irwin, McCarty, Mullin, Obernolte, Ting
ABS, ABST OR NV: Medina
ASSEMBLY FLOOR: 76-0-4
YES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Carrillo, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, O'Donnell, Obernolte, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
ABS, ABST OR NV: Calderon, Cervantes, Gloria, Kamlager
SENATE FLOOR: 39-0-1
YES: Allen, Archuleta, Atkins, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dahle, Dodd, Durazo, Galgiani, Glazer, Lena Gonzalez, Grove, Hertzberg, Hill, Hueso, Hurtado, Jackson, Leyva, McGuire, Melendez, Mitchell, Monning, Moorlach, Morrell, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Umberg, Wieckowski, Wiener, Wilk
ABS, ABST OR NV: Jones
ASSEMBLY FLOOR: 76-0-3
YES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Diep, Flora, Fong, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Waldron, Weber, Wicks, Wood, Rendon
ABS, ABST OR NV: Eggman, Frazier, Voepel
UPDATED:
VERSION: September 4, 2020
CONSULTANT: Danielle Sires / B. & P. / (916) 319-3301 FN: 0003712
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 1470
Author:(Quirk)
As Amended Ver:August 26, 2020
Majority vote
SUMMARY:
Specifies that "final form" means unpackaged cannabis product as it will be consumed.
The Senate Amendments:
- Adds double-jointing language with AB 1458 (Quirk) of the current legislative session.
- Addresses implementation issues by removing vaporized devices from the definition of final form in order to ensure accurate testing for potential lead, mercury, or harmful material contamination.
COMMENTS:
State Regulation of Cannabis. In 1996, California first legalized cannabis for medical consumption via Proposition 215, also known as the Compassionate Use Act (the Act). Proposition 215 protected qualified patients and primary caregivers from prosecution related to the possession and cultivation of cannabis for medicinal purposes. In 2003, the Legislature authorized the formation of medical marijuana cooperatives—nonprofit organizations that cultivate and distribute marijuana for medical uses to their members through dispensaries.
In 2015, the Legislature passed the Medical Cannabis Regulation and Safety Act (MCRSA). For the first time, MCRSA established a comprehensive, statewide licensing and regulatory framework for the cultivation, manufacture, transportation, testing, distribution, and sale of medicinal cannabis to be administered by the Bureau within the Department of Consumer Affairs, Department of Public Health, and California Department of Food and Agriculture.
Shortly following the passage of MCRSA in November 2016, California voters passed Proposition 64, the "Control, Regulate and Tax Adult Use of Marijuana Act" (Proposition 64), which legalized adult-use cannabis. Less than a year later in June 2017, the California State Legislature passed a budget trailer bill, SB 94 (Budget and Fiscal Review Committee, Chapter 27, Statutes of 2017), that integrated MCRSA with Prop 64 to create MAUCRSA, the current regulatory structure for both medicinal and adult-use cannabis. Beginning in 2018, Proposition 64 permitted adults 21 years of age or older can legally grow, possess, and use cannabis for nonmedical purposes, with certain restrictions.
Final Form and Testing. MAUCRSA requires cannabis in its final form to be laboratory tested prior to sale. Currently, the California Bureau of Cannabis Control has promulgated regulations that determine final form by how a consumer purchases the product from a retail location. Practically, this means that manufactured cannabis products are delivered to labs for testing in sealed, labeled retail packaging. The regulations also define a "packaged unit" as the final form of the product as it would be sold to the consumer. This includes identical packaging branding of the manufactured cannabis goods in their final form. (California Code of Regulations, Title 16, Section 5708)
This bill provides clarity to the above regulations by statutorily defining final form as the unpackaged product as it will be consumed. Further, this bill states that the cannabis or cannabis product does not have to be to the laboratory in the final retail packaging or, if applicable, within its vaporizer device, to be considered in its final form. This will prevent cannabis manufacturers from unnecessarily spending resources and creating waste to full package a product when the laboratory must extract the product from its packaging for testing. Finally, this bill will allow for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
According to the Author:
This bill is sponsored by the California Cannabis Manufacturer's Association. According to the author, "The regulated cannabis industry is at risk. The legal market has been unable to drive out the remnants of underground cannabis markets, and there are serious concerns that under the regulations as currently structured, the black market may never be driven out. AB 1470 makes commonsense changes to the laws regulating cannabis testing so that cannabis can be tested in a batch. Currently manufactured cannabis product, like extract sold in vaporizer cartridges, must be sent to laboratories in their final retail packaged form. This means labs are forced to break open cartridges, or make other laborious efforts to get at the cannabis product being tested. AB 1470 spares manufactures and laboratories the expense, making the regulated market stronger and making good on the direction the voters approved under Proposition 64."
Arguments in Support:
According to Southern California Coalition, "[a]llows cannabis manufacturers to manage testing in a more accessible and less expensive manner than is currently available to them. It is a badly needed adjustment of business practices. By allowing final form testing without packaging, you are following the practice of many other industries. [This bill] does not waive testing or quality assurance protocols. It merely simplifies the process and will save the industry time and money.
Arguments in Opposition:
None on file.
FISCAL COMMENTS:
None. This bill is keyed non fiscal by the Legislative Counsel.
VOTES:
ASM BUSINESS AND PROFESSIONS: 18-0-1
YES: Low, Brough, Arambula, Bloom, Chen, Chiu, Cunningham, Eggman, Fong, Gipson, Gloria, Grayson, Holden, Irwin, McCarty, Mullin, Obernolte, Ting
ABS, ABST OR NV: Medina
ASSEMBLY FLOOR: 76-0-4
YES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Carrillo, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, O'Donnell, Obernolte, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
ABS, ABST OR NV: Calderon, Cervantes, Gloria, Kamlager
SENATE FLOOR: 39-0-1
YES: Allen, Archuleta, Atkins, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dahle, Dodd, Durazo, Galgiani, Glazer, Lena Gonzalez, Grove, Hertzberg, Hill, Hueso, Hurtado, Jackson, Leyva, McGuire, Melendez, Mitchell, Monning, Moorlach, Morrell, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Umberg, Wieckowski, Wiener, Wilk
ABS, ABST OR NV: Jones
UPDATED:
VERSION: August 26, 2020
CONSULTANT: Danielle Sires / B. & P. / (916) 319-3301 FN: 0003659
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 1470 |
THIRD READING
Bill No: AB 1470
Author: Quirk (D)
Amended: 8/26/20 in Senate
Vote: 21
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 9-0, 8/8/20
AYES: Glazer, Chang, Archuleta, Dodd, Galgiani, Hill, Leyva, Pan, Wilk
ASSEMBLY FLOOR: 76-0, 1/23/20 - See last page for vote
SUBJECT: Cannabis testing
SOURCE: California Cannabis Manufacturers Association
DIGEST:
This bill specifies that “final form” means unpackaged cannabis product as it will be consumed.
Senate Floor Amendments of 8/26/20 add double-jointing language with AB 1458 (Quirk).
Senate Floor Amendments of 8/24/20 address implementation issues by removing vaporized devices from the definition of final form in order to ensure accurate testing for potential lead, mercury, or harmful material contamination.
ANALYSIS:
Existing law:
- Establishes the Bureau of Cannabis Control under the Department of Consumer Affairs to administer and enforce the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) and the Control, Regulate and Tax Adult Use of Marijuana Act of 2016, which establishes a comprehensive system to control and regulate the distribution, transport, storage, and sale of cannabis products. (Business and Professions Code (BPC) § 26000 et seq.)
- Requires licensed sellers of cannabis or cannabis products to have a representative sample tested by a licensed testing laboratory. (BPC § 26100(a))
- Prohibits cannabis or cannabis products from being sold pursuant to a state cannabis license, unless a representative sample has been tested by a licensed testing laboratory. Requires a presale inspection, testing transfer, or transportation of cannabis products for the purpose of laboratory testing to conform to a specified chain of custody protocol. (BPC § 26100)
- Prohibits, except as provided elsewhere in BPC Division 10, a testing laboratory from acquiring or receiving cannabis or cannabis products except from a licensee or from distributing, selling or dispensing cannabis or cannabis products from the licensed premises from which the cannabis or cannabis products were acquired or received. Requires all transfer or transportation to be performed pursuant to a specified chain of custody protocol. (BPC § 26104(c))
- Authorizes a testing laboratory to receive and test samples of cannabis or cannabis products from a qualified patient or primary caregiver, only if the qualifies patient or caregiver presents the qualified patient’s valid physician’s recommendation for cannabis for medicinal purposes. Prohibits a testing laboratory from certifying samples from a qualified patient or primary caregiver for resale or transfer to another party or licensee. Requires all tests performed by a testing laboratory for a qualified patient or primary caregiver to be recorded with the name of the qualified patient or primary caregiver and the amount of cannabis or cannabis product received. (BPC § 26104(d))
- Defines “certificate of analysis” as the report prepared by the laboratory about the analytical testing performed and results obtained by the laboratory. (California Code of Regulations (CCR), Title 16, § 5700(q))
- Requires a distributor after receipt of a certificate of analysis from a testing laboratory, or upon transfer from another distributor, before transporting the cannabis goods, to ensure, among other things, that the certificate is the proper certificate for the batch, is timely, is consistent with the label on the goods. (CCR, Title 16, § 5307)
- Defines a “packaged unit” as the final form of the product as it would be sold to the consumer. This includes identical packaging branding of the manufactured cannabis goods in their final form. (CCR, Title 16, § 5708)
This bill:
- Specifies that “final form” means the unpackaged product as it will be consumed.
- Specifies that the cannabis or cannabis product does not have to be delivered to the licensed testing laboratory in the final retail packaging or, if applicable, within its vaporizer device to be considered in its final form.
- Allows for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
Background
State Regulation of Cannabis. In 1996, California first legalized cannabis for medical consumption via Proposition 215, also known as the Compassionate Use Act (the Act). Proposition 215 protected qualified patients and primary caregivers from prosecution related to the possession and cultivation of cannabis for medicinal purposes. In 2003, the Legislature authorized the formation of medical marijuana cooperatives—nonprofit organizations that cultivate and distribute marijuana for medical uses to their members through dispensaries.
In 2015, the Legislature passed the Medical Cannabis Regulation and Safety Act (MCRSA). For the first time, MCRSA established a comprehensive, statewide licensing and regulatory framework for the cultivation, manufacture, transportation, testing, distribution, and sale of medicinal cannabis to be administered by the Bureau within the Department of Consumer Affairs, Department of Public Health, and California Department of Food and Agriculture.
Shortly following the passage of MCRSA in November 2016, California voters passed Proposition 64, the "Control, Regulate and Tax Adult Use of Marijuana Act" (Proposition 64), which legalized adult-use cannabis. Less than a year later in June 2017, the California State Legislature passed a budget trailer bill, SB 94 (Committee on Budget and Fiscal Review, Chapter 27, Statutes of 2017), that integrated MCRSA with Prop 64 to create MAUCRSA, the current regulatory structure for both medicinal and adult-use cannabis. Beginning in 2018, Proposition 64 permitted adults 21 years of age or older can legally grow, possess, and use cannabis for nonmedical purposes, with certain restrictions.
Final Form and Testing. MAUCRSA requires cannabis in its final form to be laboratory tested prior to sale. Currently, the California Bureau of Cannabis Control has promulgated regulations that determine final form by how a consumer purchases the product from a retail location. Practically, this means that manufactured cannabis products are delivered to labs for testing in sealed, labeled retail packaging. The regulations also define a “packaged unit” as the final form of the product as it would be sold to the consumer. This includes identical packaging branding of the manufactured cannabis goods in their final form. (CCR, Title 16, § 5708)
This bill provides clarity to the above regulations by statutorily defining final form as the unpackaged product as it will be consumed. Further, this bill states that the cannabis or cannabis product does not have to be to the laboratory in the final retail packaging or, if applicable, within its vaporizer device, to be considered in its final form. This will prevent cannabis manufacturers from unnecessarily spending resources and creating waste to full package a product when the laboratory must extract the product from its packaging for testing. Finally, this bill will allow for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
SUPPORT: (Verified 8/25/20)
California Cannabis Manufacturers Association (source)
California Cannabis Industry Association
Natura
Southern California Coalition
OPPOSITION: (Verified 8/25/20)
None received
ARGUMENTS IN SUPPORT: Supporters say that sending products for testing with full child-resistant packaging to a laboratory that is immediately removed not only adds unnecessary cost burden to the industry, but is an unneeded source of waste. Packaging in this way may also introduce uncertainty into the testing environment.
ASSEMBLY FLOOR: 76-0, 1/23/20
AYES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Carrillo, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
NO VOTE RECORDED: Calderon, Cervantes, Gloria, Kamlager
Prepared by: Dana Shaker / B., P. & E.D. /
8/27/20 20:43:45
**** END ****
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 1470 |
THIRD READING
Bill No: AB 1470
Author: Quirk (D)
Amended: 8/24/20 in Senate
Vote: 21
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 9-0, 8/8/20
AYES: Glazer, Chang, Archuleta, Dodd, Galgiani, Hill, Leyva, Pan, Wilk
ASSEMBLY FLOOR: 76-0, 1/23/20 - See last page for vote
SUBJECT: Cannabis testing
SOURCE: California Cannabis Manufacturers Association
DIGEST:
This bill specifies that “final form” means unpackaged cannabis product as it will be consumed.
Senate Floor Amendments of 8/24/20 address implementation issues by removing vaporized devices from the definition of final form in order to ensure accurate testing for potential lead, mercury, or harmful material contamination.
ANALYSIS:
Existing law:
- Establishes the Bureau of Cannabis Control under the Department of Consumer Affairs to administer and enforce the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) and the Control, Regulate and Tax Adult Use of Marijuana Act of 2016, which establishes a comprehensive system to control and regulate the distribution, transport, storage, and sale of cannabis products. (Business and Professions Code (BPC) § 26000 et seq.)
- Requires licensed sellers of cannabis or cannabis products to have a representative sample tested by a licensed testing laboratory. (BPC § 26100(a))
- Prohibits cannabis or cannabis products from being sold pursuant to a state cannabis license, unless a representative sample has been tested by a licensed testing laboratory. Requires a presale inspection, testing transfer, or transportation of cannabis products for the purpose of laboratory testing to conform to a specified chain of custody protocol. (BPC § 26100)
- Prohibits, except as provided elsewhere in BPC Division 10, a testing laboratory from acquiring or receiving cannabis or cannabis products except from a licensee or from distributing, selling or dispensing cannabis or cannabis products from the licensed premises from which the cannabis or cannabis products were acquired or received. Requires all transfer or transportation to be performed pursuant to a specified chain of custody protocol. (BPC § 26104(c))
- Authorizes a testing laboratory to receive and test samples of cannabis or cannabis products from a qualified patient or primary caregiver, only if the qualifies patient or caregiver presents the qualified patient’s valid physician’s recommendation for cannabis for medicinal purposes. Prohibits a testing laboratory from certifying samples from a qualified patient or primary caregiver for resale or transfer to another party or licensee. Requires all tests performed by a testing laboratory for a qualified patient or primary caregiver to be recorded with the name of the qualified patient or primary caregiver and the amount of cannabis or cannabis product received. (BPC § 26104(d))
- Defines “certificate of analysis” as the report prepared by the laboratory about the analytical testing performed and results obtained by the laboratory. (California Code of Regulations (CCR), Title 16, § 5700(q))
- Requires a distributor after receipt of a certificate of analysis from a testing laboratory, or upon transfer from another distributor, before transporting the cannabis goods, to ensure, among other things, that the certificate is the proper certificate for the batch, is timely, is consistent with the label on the goods. (CCR, Title 16, § 5307)
- Defines a “packaged unit” as the final form of the product as it would be sold to the consumer. This includes identical packaging branding of the manufactured cannabis goods in their final form. (CCR, Title 16, § 5708)
This bill:
- Specifies that “final form” means the unpackaged product as it will be consumed.
- Specifies that the cannabis or cannabis product does not have to be delivered to the licensed testing laboratory in the final retail packaging to be considered in its final form.
- Allows for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
Background
State Regulation of Cannabis. In 1996, California first legalized cannabis for medical consumption via Proposition 215, also known as the Compassionate Use Act (the Act). Proposition 215 protected qualified patients and primary caregivers from prosecution related to the possession and cultivation of cannabis for medicinal purposes. In 2003, the Legislature authorized the formation of medical marijuana cooperatives—nonprofit organizations that cultivate and distribute marijuana for medical uses to their members through dispensaries.
In 2015, the Legislature passed the Medical Cannabis Regulation and Safety Act (MCRSA). For the first time, MCRSA established a comprehensive, statewide licensing and regulatory framework for the cultivation, manufacture, transportation, testing, distribution, and sale of medicinal cannabis to be administered by the Bureau within the Department of Consumer Affairs, Department of Public Health, and California Department of Food and Agriculture.
Shortly following the passage of MCRSA in November 2016, California voters passed Proposition 64, the "Control, Regulate and Tax Adult Use of Marijuana Act" (Proposition 64), which legalized adult-use cannabis. Less than a year later in June 2017, the California State Legislature passed a budget trailer bill, SB 94 (Committee on Budget and Fiscal Review, Chapter 27, Statutes of 2017), that integrated MCRSA with Prop 64 to create MAUCRSA, the current regulatory structure for both medicinal and adult-use cannabis. Beginning in 2018, Proposition 64 permitted adults 21 years of age or older can legally grow, possess, and use cannabis for nonmedical purposes, with certain restrictions.
Final Form and Testing. MAUCRSA requires cannabis in its final form to be laboratory tested prior to sale. Currently, the California Bureau of Cannabis Control has promulgated regulations that determine final form by how a consumer purchases the product from a retail location. Practically, this means that manufactured cannabis products are delivered to labs for testing in sealed, labeled retail packaging. The regulations also define a “packaged unit” as the final form of the product as it would be sold to the consumer. This includes identical packaging branding of the manufactured cannabis goods in their final form. (CCR, Title 16, § 5708)
This bill provides clarity to the above regulations by statutorily defining final form as the unpackaged product as it will be consumed. Further, this bill states that the cannabis or cannabis product does not have to be to the laboratory in the final retail packaging to be considered in its final form. This will prevent cannabis manufacturers from unnecessarily spending resources and creating waste to full package a product when the laboratory must extract the product from its packaging for testing. Finally, this bill will allow for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
SUPPORT: (Verified 8/20/20)
California Cannabis Manufacturers Association (source)
California Cannabis Industry Association
Natura
Southern California Coalition
OPPOSITION: (Verified 8/20/20)
None received
ARGUMENTS IN SUPPORT: Supporters say that sending products for testing with full child-resistant packaging to a laboratory that is immediately removed not only adds unnecessary cost burden to the industry, but is an unneeded source of waste. Packaging in this way may also introduce uncertainty into the testing environment.
ASSEMBLY FLOOR: 76-0, 1/23/20
AYES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Carrillo, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
NO VOTE RECORDED: Calderon, Cervantes, Gloria, Kamlager
Prepared by: Dana Shaker / B., P. & E.D. /
8/25/20 15:24:44
**** END ****
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 1470 |
THIRD READING
Bill No: AB 1470
Author: Quirk (D)
Amended: 4/12/19 in Assembly
Vote: 21
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 9-0, 8/8/20
AYES: Glazer, Chang, Archuleta, Dodd, Galgiani, Hill, Leyva, Pan, Wilk
ASSEMBLY FLOOR: 76-0, 1/23/20 - See last page for vote
SUBJECT: Cannabis testing
SOURCE: California Cannabis Manufacturers Association
DIGEST:
This bill specifies that “final form” means unpackaged cannabis product as it will be consumed.
ANALYSIS:
Existing law:
- Establishes the Bureau of Cannabis Control under the Department of Consumer Affairs to administer and enforce the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) and the Control, Regulate and Tax Adult Use of Marijuana Act of 2016, which establishes a comprehensive system to control and regulate the distribution, transport, storage, and sale of cannabis products. (Business and Professions Code (BPC) § 26000 et seq.)
- Requires licensed sellers of cannabis or cannabis products to have a representative sample tested by a licensed testing laboratory. (BPC § 26100(a))
- Prohibits cannabis or cannabis products from being sold pursuant to a state cannabis license, unless a representative sample has been tested by a licensed testing laboratory. Requires a presale inspection, testing transfer, or transportation of cannabis products for the purpose of laboratory testing to conform to a specified chain of custody protocol. (BPC § 26100)
- Prohibits, except as provided elsewhere in BPC Division 10, a testing laboratory from acquiring or receiving cannabis or cannabis products except from a licensee or from distributing, selling or dispensing cannabis or cannabis products from the licensed premises from which the cannabis or cannabis products were acquired or received. Requires all transfer or transportation to be performed pursuant to a specified chain of custody protocol. (BPC § 26104(c))
- Authorizes a testing laboratory to receive and test samples of cannabis or cannabis products from a qualified patient or primary caregiver, only if the qualifies patient or caregiver presents the qualified patient’s valid physician’s recommendation for cannabis for medicinal purposes. Prohibits a testing laboratory from certifying samples from a qualified patient or primary caregiver for resale or transfer to another party or licensee. Requires all tests performed by a testing laboratory for a qualified patient or primary caregiver to be recorded with the name of the qualified patient or primary caregiver and the amount of cannabis or cannabis product received. (BPC § 26104(d))
- Defines “certificate of analysis” as the report prepared by the laboratory about the analytical testing performed and results obtained by the laboratory. (California Code of Regulations (CCR), Title 16, § 5700(q))
- Requires a distributor after receipt of a certificate of analysis from a testing laboratory, or upon transfer from another distributor, before transporting the cannabis goods, to ensure, among other things, that the certificate is the proper certificate for the batch, is timely, is consistent with the label on the goods. (CCR, Title 16, § 5307)
- Defines a “packaged unit” as the final form of the product as it would be sold to the consumer. This includes identical packaging branding of the manufactured cannabis goods in their final form. (CCR, Title 16, § 5708)
This bill:
- Specifies that “final form” means the unpackaged product as it will be consumed.
- Specifies that the cannabis or cannabis product does not have to be delivered to the licensed testing laboratory in the final retail packaging or, if applicable, within its vaporizer device to be considered in its final form.
- Allows for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
Background
State Regulation of Cannabis. In 1996, California first legalized cannabis for medical consumption via Proposition 215, also known as the Compassionate Use Act (the Act). Proposition 215 protected qualified patients and primary caregivers from prosecution related to the possession and cultivation of cannabis for medicinal purposes. In 2003, the Legislature authorized the formation of medical marijuana cooperatives—nonprofit organizations that cultivate and distribute marijuana for medical uses to their members through dispensaries.
In 2015, the Legislature passed the Medical Cannabis Regulation and Safety Act (MCRSA). For the first time, MCRSA established a comprehensive, statewide licensing and regulatory framework for the cultivation, manufacture, transportation, testing, distribution, and sale of medicinal cannabis to be administered by the Bureau within the Department of Consumer Affairs, Department of Public Health, and California Department of Food and Agriculture.
Shortly following the passage of MCRSA in November 2016, California voters passed Proposition 64, the "Control, Regulate and Tax Adult Use of Marijuana Act" (Proposition 64), which legalized adult-use cannabis. Less than a year later in June 2017, the California State Legislature passed a budget trailer bill, SB 94 (Committee on Budget and Fiscal Review, Chapter 27, Statutes of 2017), that integrated MCRSA with Prop 64 to create MAUCRSA, the current regulatory structure for both medicinal and adult-use cannabis. Beginning in 2018, Proposition 64 permitted adults 21 years of age or older can legally grow, possess, and use cannabis for nonmedical purposes, with certain restrictions.
Final Form and Testing. MAUCRSA requires cannabis in its final form to be laboratory tested prior to sale. Currently, the California Bureau of Cannabis Control has promulgated regulations that determine final form by how a consumer purchases the product from a retail location. Practically, this means that manufactured cannabis products are delivered to labs for testing in sealed, labeled retail packaging. The regulations also define a “packaged unit” as the final form of the product as it would be sold to the consumer. This includes identical packaging branding of the manufactured cannabis goods in their final form. (CCR, Title 16, § 5708)
This bill provides clarity to the above regulations by statutorily defining final form as the unpackaged product as it will be consumed. Further, this bill states that the cannabis or cannabis product does not have to be to the laboratory in the final retail packaging or, if applicable, within its vaporizer device, to be considered in its final form. This will prevent cannabis manufacturers from unnecessarily spending resources and creating waste to full package a product when the laboratory must extract the product from its packaging for testing. Finally, this bill will allow for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
SUPPORT: (Verified 8/12/20)
California Cannabis Manufacturers Association (source)
California Cannabis Industry Association
Natura
Southern California Coalition
OPPOSITION: (Verified 8/12/20)
None received
ARGUMENTS IN SUPPORT: Supporters say that sending products for testing with full child-resistant packaging to a laboratory that is immediately removed not only adds unnecessary cost burden to the industry, but is an unneeded source of waste. Packaging in this way may also introduce uncertainty into the testing environment.
ASSEMBLY FLOOR: 76-0, 1/23/20
AYES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Carrillo, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
NO VOTE RECORDED: Calderon, Cervantes, Gloria, Kamlager
Prepared by: Dana Shaker / B., P. & E.D. /
8/12/20 14:14:57
**** END ****
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Steven Glazer, Chair
2019 - 2020 Regular
Bill No: Hearing Date: August 8, 2020
Author: | |||
Version: | April 12, 2019 | ||
Urgency: | No | Fiscal: | No |
Consultant: | Dana Shaker | ||
Subject:
SUMMARY:
Specifies that “final form” means the unpackaged cannabis product as it will be consumed.
Existing law:
- Establishes the Bureau of Cannabis Control under the Department of Consumer Affairs to administer and enforce the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) and the Control, Regulate and Tax Adult Use of Marijuana Act of 2016 (AUMA), which establishes a comprehensive system to control and regulate the distribution, transport, storage, and sale of cannabis products. (Business and Professions Code (BPC) § 26000 et seq.)
- Requires licensed sellers of cannabis or cannabis products to have a representative sample tested by a licensed testing laboratory. (BPC § 26100(a))
- Requires all commercial cannabis activity to be conducted between licenses, with specified exceptions. (BPC § 26053)
- Prohibits cannabis or cannabis products from being sold pursuant to a state cannabis license, unless a representative sample has been tested by a licensed testing laboratory. Requires a presale inspection, testing transfer, or transportation of cannabis products for the purpose of laboratory testing to conform to a specified chain of custody protocol. (BPC § 26100)
- Except as provided elsewhere in Division 10 of the Business and Professions Code, prohibits a testing laboratory from acquiring or receiving cannabis or cannabis products except from a licensee or from distributing, selling or dispensing cannabis or cannabis products from the licensed premises from which the cannabis or cannabis products were acquired or received. (BPC § 26104(c))
- Requires all transfer or transportation to be performed pursuant to a specified chain of custody protocol. (BPC § 26104(c))
- Authorizes a testing laboratory to receive and test samples of cannabis or cannabis products from a qualified patient or primary caregiver, only if the qualifies patient or caregiver presents the qualified patient’s valid physician’s recommendation for cannabis for medicinal purposes. Prohibits a testing laboratory from certifying samples from a qualified patient or primary caregiver for resale or transfer to another party or licensee. Requires all tests performed by a testing laboratory for a qualified patient or primary caregiver to be recorded with the name of the qualified patient or primary caregiver and the amount of cannabis or cannabis product received. (BPC § 26104(d))
- Defines “certificate of analysis” as the report prepared by the laboratory about the analytical testing performed and results obtained by the laboratory. (California Code of Regulations (CCR), Title 16, § 5700(q))
- Requires a distributor after receipt of a certificate of analysis from a testing laboratory, or upon transfer from another distributor, before transporting the cannabis goods, to ensure, among other things, that the certificate is the proper certificate for the batch, is timely, is consistent with the label on the goods. (CCR, Title 16, § 5307)
- Defines a “packaged unit” as the final form of the product as it would be sold to the consumer. This includes identical packaging branding of the manufactured cannabis goods in their final form. (CCR, Title 16, § 5708)
This bill:
- Specifies that “final form” means the unpackaged product as it will be consumed.
- Specifies that the cannabis or cannabis product does not have to be delivered to the licensed testing laboratory in the final retail packaging or, if applicable, within its vaporizer device to be considered in its final form.
- Allows for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
FISCAL EFFECT:
Unknown. This bill is not keyed fiscal by Legislative Counsel.
COMMENTS:
- Purpose. This California Cannabis Manufacturer’s Association is the Sponsor of this bill. According to the Author, “Business and Professions Code §26100 details cannabis testing, however, is not specific as to what it means for cannabis product to be in its final forms. Currently, the California Bureau of Cannabis Control has promulgated regulations to define final form as how a consumer purchases the product from a retail location, inside costly and ecologically unfriendly childproof packaging.
Conducting tests on fully sealed and packaged product is wasteful and introduces uncertainty to the testing environment. Cannabis manufacturers must expend resources on the labor and material to fully package the product, which is then wasted when the laboratory must extract the product from its packaging. For example, for cannabis extract sold in vaporizing cartridges, the extract must be sent to the lab in the cartridge and retail box. The cartridge must then be broken open to retrieve the extract for testing…. AB 1470 adds specificity to the term “final form” as it appears in the Business and Professions code relating to manufactured products. AB 1470 will allow for batch testing of manufactured cannabis products in their final form prior to retail packaging, as opposed to testing retail packaged units only.”
- Background.
State Regulation of Cannabis. In 1996, California first
legalized cannabis for medical consumption via Proposition 215, also known as the
Compassionate Use Act (the Act). Proposition 215 protected qualified patients and primary caregivers from prosecution related to the possession and cultivation of cannabis for medicinal purposes. In 2003, the Legislature authorized the formation of medical marijuana cooperatives—nonprofit organizations that cultivate and distribute marijuana for medical uses to their members through dispensaries.
In 2015, the Legislature passed the Medical Cannabis Regulation and Safety Act (MCRSA). For the first time, MCRSA established a comprehensive, statewide licensing and regulatory framework for the cultivation, manufacture, transportation, testing, distribution, and sale of medicinal cannabis to be administered by the Bureau within Department of Consumer Affairs, DPH, and CDFA.
Shortly following the passage of MCRSA in November 2016, California voters passed Proposition 64, the "Control, Regulate and Tax Adult Use of Marijuana Act" (Proposition 64), which legalized adult-use cannabis. Less than a year later in June 2017, the California State Legislature passed a budget trailer bill, SB 94 (Committee on Budget and Fiscal Review, Chapter 27, Statutes of 2017), that integrated MCRSA with Prop 64 to create MAUCRSA, the current regulatory structure for both medicinal and adult-use cannabis. Beginning in 2018, Proposition 64 permitted adults 21 years of age or older can legally grow, possess, and use cannabis for nonmedical purposes, with certain restrictions.
Final Form and Testing. MAUCRSA requires cannabis in its final form to be laboratory tested prior to sale. Currently, the California Bureau of Cannabis Control has promulgated regulations that determine final form by how a consumer purchases the product from a retail location. Practically, this means that manufactured cannabis products are delivered to labs for testing in sealed, labeled retail packaging. The regulations also define a “packaged unit” as the final form of the product as it would be sold to the consumer. This includes identical packaging branding of the manufactured cannabis goods in their final form. (CCR, Title 16, § 5708)
This bill provides clarity to the above regulations by statutorily defining final form as the unpackaged product as it will be consumed. Further, the bill states that the cannabis or cannabis product does not have to be to the laboratory in the final retail packaging or, if applicable, within its vaporizer device, to be considered in its final form. This will prevent cannabis manufacturers from unnecessarily spending resources and creating waste to full package a product when the laboratory must extract the product from its packaging for testing. Finally, the bill will allow for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged
- Arguments in Support. The California Cannabis Industry Association writes in support: “Cannabis regulations specify that testing must occur in the cannabis product’s final form. Currently, “final form” is defined as a product being in its sealed packaging, as would be found on retail shelves. As a result, for purposes of compliance testing, businesses are sealing products in full child-resistant packaging before sending them to a laboratory, only for laboratories to open up and discard the packaging in order to accurately test the product. This not only adds an unnecessary cost burden to the industry, but is a major source of unneeded waste.
By changing the definition of “final form” to make clear products do not need to be in their retail packaging or vaporizer device in order to be tested, businesses can save time and resources, and laboratories can test products more expeditiously. Moreover, this small definition change will cut back significantly on the waste produced during the testing process, helping the cannabis industry move toward more sustainable practices.”
The California Cannabis Manufacturers Association (CCMA) writes in support: “Business and Professions Code 26100 details cannabis testing, however, is not specific as to what it means for cannabis product to be in its final forms. Currently, the California Bureau of Cannabis Control has promulgated regulations to define final form as how a consumer purchases the product from a retail location, inside costly and ecologically unfriendly childproof packaging.
Conducting tests on fully sealed and packaged products is wasteful and introduces uncertainty to the testing environment. Cannabis manufacturers must expend resources on the labor and material to fully package the product, which is then wasted when the laboratory must extract the product form its packaging.
AB 1470 prevents unnecessary waste and cost while still maintaining testing integrity. For these reasons, CCMA strongly supports AB 1470.”
Natura writes in support: “AB 1470 specifies that for this purpose, ‘final form’ means the unpackaged product that will be consumed. This further clarifies that the cannabis or cannabis product does not have to be delivered to the licensed testing laboratory in the final retail packaging or, if batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.”
Southern California Coalition writes in support: “AB 1470 allows cannabis manufacturers to manage testing in a more accessible and less expensive manner than is currently available to them. It is a badly needed adjustment of business practices. By allowing final form testing without packaging, you are following the practice of many other industries. AB 1470 does not waive testing or quality assurance protocols. It merely simplifies the process and will save the industry time and money.”
SUPPORT AND OPPOSITION:
Support:
California Cannabis Manufacturers Association (Sponsor)
California Cannabis Industry Association
Natura
Southern California Coalition
Opposition:
None on file.
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1470
Author:(Quirk)
As Amended Ver:April 12, 2019
Majority vote
SUMMARY:
Specifies that for this purpose "final form" means the unpackaged product as it will be consumed.
Major Provisions
- Specifies that for this purpose "final form" means the unpackaged product as it will be consumed.
- Specifies that the cannabis or cannabis product does not have to be delivered to the licensed testing laboratory in the final retail packaging or, if applicable, within its vaporizer device to be considered in its final form.
- Allows for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
- Defines "final form" as "the unpackaged product as it will be consumed." Further, "The cannabis or cannabis product does not have to be to the laboratory in the final retail packaging to be considered in its final form".
COMMENTS:
In 1996, California voters passed Proposition 215, legalizing the use of medical cannabis (MC) in the state. In October 2015, nearly 20 years after the authorization of the use of MC, Governor Jerry Brown signed into law a trio of bills; collectively known as MCRSA. In 2016, the voters of California passed Proposition 64, the Adult Use of Marijuana Act (AUMA), to legalize the recreational use of cannabis in the state by 2018.
The authors of AUMA sought to make use of much of the regulatory structure and authorities set out by MCRSA while making a few notable changes to the structure being implemented. In addition, the AUMA approved by the voters adopted the January 1, 2018 deadline for state implementation of recreational cannabis in addition to the regulations required in MCRSA that are scheduled to take effect on the same date.
Under AUMA, the Department of Consumer Affairs (DCA), continues to serve as the lead regulatory agency for all cannabis, both medical and non-medical, and renames the existing Bureau of Medical Cannabis Regulation as the Bureau of Marijuana Control. AUMA includes 19 different license types compared to the 17 in MCRSA and authorizes DCA (and the Bureau) the exclusive authority to create and regulate a license for transportation of cannabis.
Currently the California Bureau of Cannabis Control has promulgated regulations which define final form as how a consumer purchases the product from a retail location. This means that manufactured cannabis products are delivered to labs for testing in sealed, labeled retail packaging.
According to the California Code of regulations, Title 16, Division 42, Bureau of Cannabis Control, Section 5705. General Sampling Requirements. a) The laboratory that obtains a representative sample from a licensed distributor or licensed microbusiness shall perform all the required testing at one licensed laboratory premises and b) The laboratory may obtain and analyze samples only from batches in final form as required by Business and Professions Code Section 26100.
On January 15, 2019 the addendum to the final statement of reasons, issued by the Bureau of Cannabis Control was released, and states:
Testing procedure violations were also added to Tier 2 violation descriptions, including the failure to present an entire cannabis goods batch with accurate information and in its final form, reporting results when laboratory quality control data is outside of acceptance criteria or not properly analyzed, failure to follow good laboratory practices, failure to obtain a representative sample, and unauthorized re-sample or re-testing.
According to the Author:
This bill is sponsored by the California Cannabis Manufacturer's Association. According to the author, "The regulated cannabis industry is at risk. The legal market has been unable to drive out the remnants of underground cannabis markets, and there are serious concerns that under the regulations as currently structured, the black market may never be driven out. AB 1470 makes commonsense changes to the laws regulating cannabis testing so that cannabis can be tested in a batch. Currently manufactured cannabis product, like extract sold in vaporizer cartridges, must be sent to laboratories in their final retail packaged form. This means labs are forced to break open cartridges, or make other laborious efforts to get at the cannabis product being tested. AB 1470 spares manufactures and laboratories the expense, making the regulated market stronger and making good on the direction the voters approved under Proposition 64."
Arguments in Support:
According to Southern California Coalition, "[a]llows cannabis manufacturers to manage testing in a more accessible and less expensive manner than is currently available to them. It is a badly needed adjustment of business practices. By allowing final form testing without packaging, you are following the practice of many other industries. [This bill] does not waive testing or quality assurance protocols. It merely simplifies the process and will save the industry time and money.
Arguments in Opposition:
None on file.
FISCAL COMMENTS:
None. This bill is keyed non fiscal by Legislative Counsel.
VOTES:
ASM BUSINESS AND PROFESSIONS: 18-0-1
YES: Low, Brough, Arambula, Bloom, Chen, Chiu, Cunningham, Eggman, Fong, Gipson, Gloria, Grayson, Holden, Irwin, McCarty, Mullin, Obernolte, Ting
ABS, ABST OR NV: Medina
UPDATED:
VERSION: April 12, 2019
CONSULTANT: Danielle Sires / B. & P. / (916) 319-3301 FN: 0002609
Date of Hearing: January 14, 2020
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Evan Low, Chair
ABPCA Bill Id:AB 1470
Author:(Quirk) – As Amended Ver:April 12, 2019
SUBJECT: Cannabis testing.
SUMMARY: Specifies that for this purpose “final form” means the unpackaged product as it will be consumed.
EXISTING LAW:
- Establishes the Bureau of Marijuana Control, also referred to as the Bureau of Medical Cannabis Regulation (Bureau), under the Department of Consumer Affairs (DCA), to establish a comprehensive system to control and regulate the cultivation, distribution, transport, storage, manufacturing, processing, and sale of cannabis products. (Business and Professions Code (BPC) § 26000 et seq.; BPC § 19302)
- Requires licensed sellers of cannabis or cannabis products to have a representative sample tested by a licensed testing laboratory. (BPC § 26100)
- Requires all commercial cannabis activity to be conducted between licenses, with specified exceptions. (BPC § 26053)
- Prohibits cannabis or cannabis products from being sold pursuant to a state cannabis license, unless a representative sample has been tested by a licensed testing laboratory. Requires a presale inspection, testing transfer, or transportation of cannabis products for the purpose of laboratory testing to conform to a specified chain of custody protocol. (BPC § 26100)
- Except as provided elsewhere in Division 10 of the Business and Professions Code, prohibits a testing laboratory from acquiring or receiving cannabis or cannabis products except from a licensee or from distributing, selling or dispensing cannabis or cannabis products from the licensed premises from which the cannabis or cannabis products were acquired or received. (BPC § 26104(c))
- Requires all transfer or transportation to be performed pursuant to a specified chain of custody. (BPC § 26104(c))
- Authorizes a testing laboratory to receive and test samples of cannabis or cannabis products from a qualified patient or primary caregiver, only if the qualifies patient or caregiver presents the qualified patient’s valid physician’s recommendation for cannabis for medicinal purposes. Prohibits a testing laboratory from certifying samples from a qualified patient or primary caregiver for resale or transfer to another party or licensee. Requires all tests performed by a testing laboratory for a qualified patient or primary caregiver to be recorded with the name of the qualified patient or primary caregiver and the amount of cannabis or cannabis product received. (BPC § 26104 defines “certificate of analysis” as the report prepared by the laboratory about the analytical testing performed and results obtained by the laboratory. (California Code of Regulations (CCR), Title 16, § 5700(q))
- Requires a distributor after receipt of a certificate of analysis from a testing laboratory, or upon transfer from another distributor, before transporting the cannabis goods, to ensure, among other things, that the certificate is the proper certificate for the batch, is timely, is consistent with the label on the goods. (CCR, tit. 16, § 5307)
THIS BILL:
- Specifies that for this purpose “final form” means the unpackaged product as it will be consumed.
- Specifies that the cannabis or cannabis product does not have to be delivered to the licensed testing laboratory in the final retail packaging or, if applicable, within its vaporizer device to be considered in its final form.
- Allows for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
- Defines “final form” as “the unpackaged product as it will be consumed.” Further, “The cannabis or cannabis product does not have to be to the laboratory in the final retail packaging to be considered in its final form”.
FISCAL EFFECT: None. This bill is keyed non fiscal by Legislative Counsel.
COMMENTS:
Purpose. This bill is sponsored by the California Cannabis Manufacturer’s Association. According to the author, “The regulated cannabis industry is at risk. The legal market has been unable to drive out the remnants of underground cannabis markets, and there are serious concerns that under the regulations as currently structured, the black market may never be driven out. AB 1470 makes commonsense changes to the laws regulating cannabis testing so that cannabis can be tested in a batch. Currently manufactured cannabis product, like extract sold in vaporizer cartridges, must be sent to laboratories in their final retail packaged form. This means labs are forced to break open cartridges, or make other laborious efforts to get at the cannabis product being tested. AB 1470 spares manufactures and laboratories the expense, making the regulated market stronger and making good on the direction the voters approved under Proposition 64.”
Background. Cannabis Regulation in California. In 1996, California voters passed Proposition 215, legalizing the use of medical cannabis (MC) in the state. In October 2015, nearly 20 years after the authorization of the use of MC, Governor Jerry Brown signed into law a trio of bills [AB 243 (Wood), Chapter 688, Statutes of 2015, AB 266 (Bonta, Cooley, Jones-Sawyer, Lackey, and Wood), Chapter 689, Statutes of 2015, and SB 643 (McGuire), Chapter 719, Statutes of 2015] collectively known as MCRSA. MCRSA established the state's first regulatory framework for MC. In 2016, the voters of California passed Proposition 64, the Adult Use of Marijuana Act (AUMA), to legalize the recreational use of cannabis in the state by 2018.
The authors of AUMA sought to make use of much of the regulatory structure and authorities set out by MCRSA while making a few notable changes to the structure being implemented. In addition, the AUMA approved by the voters adopted the January 1, 2018 deadline for state implementation of recreational cannabis in addition to the regulations required in MCRSA that are scheduled to take effect on the same date. The same agencies as under MCRSA remain responsible for implementing regulations for adult use.
Under AUMA, the Department of Consumer Affairs (DCA), continues to serve as the lead regulatory agency for all cannabis, both medical and non-medical, and renames the existing Bureau of Medical Cannabis Regulation as the Bureau of Marijuana Control. AUMA includes 19 different license types compared to the 17 in MCRSA and authorizes DCA (and the Bureau) the exclusive authority to create and regulate a license for transportation of cannabis.
Currently the California Bureau of Cannabis Control has promulgated regulations which define final form as how a consumer purchases the product from a retail location. This means that manufactured cannabis products are delivered to labs for testing in sealed, labeled retail packaging.
According to the California Code of regulations, Title 16, Division 42, Bureau of Cannabis Control, § 5705. General Sampling Requirements. (a) The laboratory that obtains a representative sample from a licensed distributor or licensed microbusiness shall perform all the required testing at one licensed laboratory premises and (b) The laboratory may obtain and analyze samples only from batches in final form as required by BPC § 26100.
On January 15, 2019 the addendum to the final statement of reasons, issued by the Bureau of Cannabis Control was released, and states:
Testing procedure violations were also added to Tier 2 violation descriptions, including the failure to present an entire cannabis goods batch with accurate information and in its final form, reporting results when laboratory quality control data is outside of acceptance criteria or not properly analyzed, failure to follow good laboratory practices, failure to obtain a representative sample, and unauthorized re-sample or re-testing. This was necessary to make distinct certain requirements and violations from other similar violations of testing requirements under Tier 2.
Current Related Legislation. AB1458 (Quirk) of the current Legislative Session, makes technical, non-substantive changes to the Business and Professions Code Section 26100, which describes procedures and requirements for testing cannabis and cannabis products.
Prior Related Legislation. SB 837 (Budget and Fiscal Review, Chapter 32, Statutes of 2016) clarified that licensed operators may test cannabis and cannabis products in-house for quality assurance purposes.
AB 243 (Wood, Chapter 688, Statutes of 2015) requires CDFA, DPR, the State Department of Public Health, the Department of Fish and Wildlife, and the State Water Resources Control Board to promulgate regulations or standards relating to medical cannabis and its cultivation, as specified, and establishes licensing fees, fines, and penalties.
AB 266 (Bonta et al., Chapter 689, Statutes of 2015) established the Act for the licensure and regulation of medical cannabis and establishes the Bureau of Medical Cannabis Regulation within the DCA.
SB 643 (McGuire, Chapter 719, Statutes of 2015) set standards for the licensed cultivation and physician prescription of medical cannabis; establishes a track and trace program for the transportation of medical cannabis; and authorizes counties to impose a tax on medical cannabis.
ARGUMENTS IN SUPPORT:
According to Southern California Coalition, “[a]llows cannabis manufacturers to manage testing in a more accessible and less expensive manner than is currently available to them. It is a badly needed adjustment of business practices. By allowing final form testing without packaging, you are following the practice of many other industries. [This bill] does not waive testing or quality assurance protocols. It merely simplifies the process and will save the industry time and money.
ARGUMENTS IN OPPOSITION:
None on file.
IMPLEMENTATION ISSUES:
The author may want to consider that contamination of cannabis products that occurs when a cannabis product is packaged in a dirty or contaminated container could be missed on moving to batch testing.
REGISTERED SUPPORT:
California Cannabis Manufacturers Association (Sponsor)
Natura
Osiris Ventures
Southern California Coalition
REGISTERED OPPOSITION:
None on file.
Analysis Prepared by: Danielle Sires / B. & P. / (916) 319-3301
Date of Hearing: April 23, 2019
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Evan Low, Chair
ABPCA Bill Id:AB 1470
Author:(Quirk) – As Amended Ver:April 22, 2019
SUBJECT: Cannabis testing.
SUMMARY: Specifies that for this purpose “final form” means the unpackaged product as it will be consumed.
EXISTING LAW:
- Establishes the Bureau of Marijuana Control, also referred to as the Bureau of Medical Cannabis Regulation (Bureau), under the Department of Consumer Affairs (DCA), to establish a comprehensive system to control and regulate the cultivation, distribution, transport, storage, manufacturing, processing, and sale of cannabis products. (Business and Professions Code (BPC) § 26000 et seq.; BPC § 19302)
- Requires licensed sellers of cannabis or cannabis products to have a representative sample tested by a licensed testing laboratory. (BPC § 26100)
- Requires all commercial cannabis activity to be conducted between licenses, with specified exceptions. (BPC § 26053)
- Prohibits cannabis or cannabis products from being sold pursuant to a state cannabis license, unless a representative sample has been tested by a licensed testing laboratory. Requires a presale inspection, testing transfer, or transportation of cannabis products for the purpose of laboratory testing to conform to a specified chain of custody protocol. (BPC § 26100)
- Except as provided elsewhere in Division 10 of the Business and Professions Code, prohibits a testing laboratory from acquiring or receiving cannabis or cannabis products except from a licensee or from distributing, selling or dispensing cannabis or cannabis products from the licensed premises from which the cannabis or cannabis products were acquired or received. (BPC § 26104(c))
- Requires all transfer or transportation to be performed pursuant to a specified chain of custody. (BPC § 26104(c))
- Authorizes a testing laboratory to receive and test samples of cannabis or cannabis products from a qualified patient or primary caregiver, only if the qualifies patient or caregiver presents the qualified patient’s valid physician’s recommendation for cannabis for medicinal purposes. Prohibits a testing laboratory from certifying samples from a qualified patient or primary caregiver for resale or transfer to another party or licensee. Requires all tests performed by a testing laboratory for a qualified patient or primary caregiver to be recorded with the name of the qualified patient or primary caregiver and the amount of cannabis or cannabis product received. (BPC § 26104 defines “certificate of analysis” as the report prepared by the laboratory about the analytical testing performed and results obtained by the laboratory. (California Code of Regulations (CCR), Title 16, § 5700(q))
- Requires a distributor after receipt of a certificate of analysis from a testing laboratory, or upon transfer from another distributor, before transporting the cannabis goods, to ensure, among other things, that the certificate is the proper certificate for the batch, is timely, is consistent with the label on the goods. (CCR, tit. 16, § 5307)
THIS BILL:
- Specifies that for this purpose “final form” means the unpackaged product as it will be consumed.
- Specifies that the cannabis or cannabis product does not have to be delivered to the licensed testing laboratory in the final retail packaging or, if applicable, within its vaporizer device to be considered in its final form.
- Allows for batch testing of manufactured cannabis, as opposed to testing of selected, retail packaged representative samples.
- Defines “final form” as “the unpackaged product as it will be consumed.” Further, “The cannabis or cannabis product does not have to be to the … laboratory in the final retail packaging to be considered in its final form”
FISCAL EFFECT: None. This bill is keyed non fiscal by Legislative Counsel.
COMMENTS:
Purpose. This bill is sponsored by the California Cannabis Manufacturer’s Association. According to the author, “The regulated cannabis industry is at risk. The legal market has been unable to drive out the remnants of underground cannabis markets, and there are serious concerns that under the regulations as currently structured, the black market may never be driven out. AB 1470 makes commonsense changes to the laws regulating cannabis testing so that cannabis can be tested in a batch. Currently manufactured cannabis product, like extract sold in vaporizer cartridges, must be sent to laboratories in their final retail packaged form. This means labs are forced to break open cartridges, or make other laborious efforts to get at the cannabis product being tested. AB 1470 spares manufactures and laboratories the expense, making the regulated market stronger and making good on the direction the voters approved under Proposition 64.”
Background. Cannabis Regulation in California. In 1996, California voters passed Proposition 215, legalizing the use of medical cannabis (MC) in the state. In October 2015, nearly 20 years after the authorization of the use of MC, Governor Jerry Brown signed into law a trio of bills [AB 243 (Wood), Chapter 688, Statutes of 2015, AB 266 (Bonta, Cooley, Jones-Sawyer, Lackey, and Wood), Chapter 689, Statutes of 2015, and SB 643 (McGuire), Chapter 719, Statutes of 2015] collectively known as MCRSA. MCRSA established the state's first regulatory framework for MC. In 2016, the voters of California passed Proposition 64, the Adult Use of Marijuana Act (AUMA), to legalize the recreational use of cannabis in the state by 2018.
The authors of AUMA sought to make use of much of the regulatory structure and authorities set out by MCRSA while making a few notable changes to the structure being implemented. In addition, the AUMA approved by the voters adopted the January 1, 2018 deadline for state implementation of recreational cannabis in addition to the regulations required in MCRSA that are scheduled to take effect on the same date. The same agencies as under MCRSA remain responsible for implementing regulations for adult use.
Under AUMA, the Department of Consumer Affairs (DCA), continues to serve as the lead regulatory agency for all cannabis, both medical and non-medical, and renames the existing Bureau of Medical Cannabis Regulation as the Bureau of Marijuana Control. AUMA includes 19 different license types compared to the 17 in MCRSA and authorizes DCA (and the Bureau) the exclusive authority to create and regulate a license for transportation of cannabis.
Currently the California Bureau of Cannabis Control has promulgated regulations which define final form as how a consumer purchases the product from a retail location. This means that manufactured cannabis products are delivered to labs for testing in sealed, labeled retail packaging.
According to the California Code of regulations, Title 16, Division 42, Bureau of Cannabis Control, § 5705. General Sampling Requirements. (a) The laboratory that obtains a representative sample from a licensed distributor or licensed microbusiness shall perform all the required testing at one licensed laboratory premises and (b) The laboratory may obtain and analyze samples only from batches in final form as required by BPC § 26100.
On January 15, 2019 the addendum to the final statement of reasons, issued by the Bureau of Cannabis Control was released, and states:
Testing procedure violations were also added to Tier 2 violation descriptions, including the failure to present an entire cannabis goods batch with accurate information and in its final form, reporting results when laboratory quality control data is outside of acceptance criteria or not properly analyzed, failure to follow good laboratory practices, failure to obtain a representative sample, and unauthorized re-sample or re-testing. This was necessary to make distinct certain requirements and violations from other similar violations of testing requirements under Tier 2.
Current Related Legislation.
AB1458 (Quirk) of the current Legislative Session, makes technical, non-substantive changes to the Business and Professions Code Section 26100, which describes procedures and requirements for testing cannabis and cannabis products.
AB1461 (Quirk) of the current Legislative Session, makes technical, non-substantive changes to the Business and Professions Code Section 26104, which describes several obligations and restrictions relating to cannabis testing laboratories.
Prior Related Legislation.
SB 837 (Budget and Fiscal Review, Chapter 32, Statutes of 2016) clarified that licensed operators may test cannabis and cannabis products in-house for quality assurance purposes.
AB 243 (Wood, Chapter 688, Statutes of 2015) requires CDFA, DPR, the State Department of Public Health, the Department of Fish and Wildlife, and the State Water Resources Control Board to promulgate regulations or standards relating to medical cannabis and its cultivation, as specified, and establishes licensing fees, fines, and penalties.
AB 266 (Bonta et al., Chapter 689, Statutes of 2015) established the Act for the licensure and regulation of medical cannabis and establishes the Bureau of Medical Cannabis Regulation within the DCA.
SB 643 (McGuire, Chapter 719, Statutes of 2015) set standards for the licensed cultivation and physician prescription of medical cannabis; establishes a track and trace program for the transportation of medical cannabis; and authorizes counties to impose a tax on medical cannabis.
ARGUMENTS IN SUPPORT:
According to Southern California Coalition, “[a]llows cannabis manufacturers to manage testing in a more accessible and less expensive manner than is currently available to them. It is a badly needed adjustment of business practices. By allowing final form testing without packaging, you are following the practice of many other industries. [This bill] does not waive testing or quality assurance protocols. It merely simplifies the process and will save the industry time and money.
ARGUMENTS IN OPPOSITION:
None on file.
POLICY ISSUE(S) FOR CONSIDERATION:
Presently, the California Bureau of Cannabis Control regulates what this bill is aiming to do. Ample adjustments, in the short time the California Bureau of Cannabis Control has been in existence, have been made. This bill may be regarded as unnecessary as there are current and recently updated regulations.
IMPLEMENTATION ISSUES:
The author may want to consider that contamination of cannabis products that occurs when a cannabis product is packaged in a dirty or contaminated container could be missed on moving to batch testing.
REGISTERED SUPPORT:
Southern California Coalition
REGISTERED OPPOSITION:
None on file.
Analysis Prepared by: Danielle Sires / B. & P. / (916) 319-3301
Bill Author
Bill Co-Author(s):